Clinical trial
A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01123785 is registered in ClinicalTrials.gov with Inotek Pharmaceuticals Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- May 31, 2010
- Completion date
- January 31, 2012
- Enrollment
- 144 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.